Carestream Health was awarded 64 patents from the U.S. Patent and Trademark Office in 2013 for innovations in radiology imaging, healthcare IT, dental imaging and other areas, reflecting another successful year in developing advanced technology across its global businesses.

Barco, a worldwide leader in enterprise visualization, has teamed up with Mammography Education Inc. to supply its latest mammography display systems and dedicated support for hands-on mammography CME courses designed to teach radiologists how to detect early-phase breast cancers.

Intensive imaging or carcinoembryonic antigen (CEA) screening each gave an increased rate of surgical treatment of recurrence with curative intent compared with minimal follow-up for patients who had undergone curative surgery for primary colorectal cancer, according to a study published online Jan. 15 by JAMA. Combining modalities failed to provide any advantage.

Veterans Health Administration National Teleradiology Program (VA-NTP) is deploying its critical case management platform for all VA-NTP customers. Radiology staff serving Veterans in VA Medical Centers partnering with VA-NTP can get rapid turnaround for STAT Interpretations from NTP as well as continuous tracking of critical case data.

A new label-free molecular imaging system called the 3D nanoSIMS could provide superior drug research studies at intensely tiny spatial resolutions, announced the National Physical Laboratory in Middlesex, United Kingdom, on Dec. 10.

Average survival for metastatic melanoma patients is less than 5 percent after five years—a disheartening figure, but an investigational agent incorporating benzamide in a melanin-targeted SPECT radiotracer could change the numbers, according to a study published Nov. 16 in the Journal of Nuclear Medicine.

Two novel cardiovascular PET agents are in the wings from FluoroPharma Medical, according to a recent profile in Forbes magazine.

The usual subjects in the Alzheimer’s brain are patterns of beta-amyloid plaque and tau aggregation, but a third perpetrator, clusterin, may be playing a more important role in the development of the disease than previously thought, according to a study published Dec. 30 in JAMA Neurology.